NEW YORK (GenomeWeb News) – Gen-Probe said today that it has inked an agreement to distribute Life Technologies' SeCore Human Leukocyte Antigen Sequence-Based Typing kits for use with the 3500 Dx Genetic Analyzer.
Under the agreement, Gen-Probe's LifeCodes business unit will have co-exclusive rights to sell the SeCore SBT line in the transplant market alongside Life Technologies' HLA sales force in the US.
Gen-Probe said LifeCodes plans to begin selling the SeCore HLA SBT line this month. The line is cleared for research use only, the company said, and not for diagnostic purposes.
Gen-Probe said that the distribution agreement follows on a supply and collaboration pact signed between the companies last year, under which Gen-Probe gained the rights to commercialize tests based on sequencing and fragment analysis to run on Life Tech's 3500 Dx Genetic Analyzer.
"With the growing importance of sequencing in transplant diagnostics, the SeCore HLA SBT product line will play a significant role in future growth by rounding out our product portfolio with one of the highest resolution offerings in molecular typing," LifeCodes GM Shawn Marcell said in a statement.
"This relationship was established to offer customers greater flexibility and access to high-resolution typing solutions with efficient workflows," added Todd Laird, GM of Life Technologies' transplant business.